Amsterdam, Netherlands – October 8, 2015—ClearFlow Inc., a medical device company based in Anaheim, California, USA, exhibited its innovative PleuraFlow® Active Clearance Technology® System at the 29th annual Association for Cardio-Thoracic Surgery (EACTS) meeting in Amsterdam this week. The EACTS Annual Meeting is the largest cardio-thoracic meeting in the world, a position it has maintained for over a decade, and this year’s event featured ClearFlow’s PleuraFlow technology for the first time. The PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting after heart surgery. Earlier this year, clinical investigators from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology
ClearFlow Participates in Clinical Panel Presentations and Round Table at Conference Focused on Clinical Impact of Retained Blood Washington, DC – October 6, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the subject of chest tube patency standards to prevent Retained Blood Syndrome (RBS) following cardiothoracic surgery last Friday at the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac surgery intensive care leaders from around the world gathered at the conference, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, DC. CVT Critical Care Conference is one of the premier settings for cardiac critical care exchange of ideas.
Anaheim, CA – June 03, 2015— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted expanded Indications for Use of the company’s patented PleuraFlow® Active Clearance Technology® System. The PleuraFlow System is a patented medical device that prevents chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate are known as Retained Blood Syndrome (RBS). These clinical complications have significant economic consequences, namely higher costs
Anaheim, CA – May 11, 2015— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that cardiac critical care investigators presented data last week at the 62nd annual German Anesthesia Congress (DAC 2015) in Düsseldorf, Germany about outcomes in patients who develop Retained Blood Syndrome (RBS) from incomplete blood evacuation after cardiac surgery. Cardiac Anesthesia specialists from Charité University Hospital Berlin’s Department of Anesthesiology and Intensive Care Medicine reported data showing that patients who developed RBS took longer to wean from the ventilator after surgery, stayed in the ICU longer (increase of 10 days), had longer hospital lengths of stay and suffered increased mortality. The clinical data was obtained
Seattle, WA–April 27, 2015—A panel of distinguished heart surgeons from leading cardiac centers shared their experiences and strategies to optimize patient recovery after cardiothoracic surgery at a panel discussion in Seattle yesterday. Of emphasis was the ongoing challenge of high complication rates for patients struggling with postoperative acute, sub-acute and chronic complications after surgery due to inadequate drainage, known as Retained Blood Syndrome (RBS).